Neuren Pharmaceuticals
Pharmaceutical ManufacturingAuckland, New Zealand11-50 Employees
Neuren Pharmaceuticals Limited is a biopharmaceutical company based in Auckland, New Zealand, focused on developing therapies for brain injury and neurodegeneration. Its work targets both acute brain injuries such as traumatic brain injury and chronic conditions including Parkinson’s and Alzheimer’s diseases. In April 2026, Neuren launched DAYBUE STIX in the United States to advance Rett syndrome treatment. The firm has pursued regulatory progress for NNZ-2591, including FDA Fast Track designations for various neurodevelopmental indications. It has also engaged in partnerships and collaborations, such as with Hope for HIE and BioLogic Pharma Solutions, to support development in related conditions and improve understanding of SHANK3 variations in Phelan-McDermid syndrome.